Trials

Phase 0 trials offer real human PK data at microdose levels—but alone, they can’t predict full-dose behavior for every compound. To bridge this gap, researchers increasingly rely on in silico modeling and physiologically based pharmacokinetic (PBPK) simulations. These computational approaches improve dose predictions, inform study design, and support go/no-go decisions—especially when clinical data is sparse.

What is In Silico Modeling?

In silico modeling refers to computer-based simulations that predict how a drug behaves in the human body based on physicochemical and biological parameters. When combined with actual Phase 0 data, these models enhance insight into absorption, distribution, metabolism, and excretion (ADME).

What is PBPK Modeling?

Physiologically Based Pharmacokinetic (PBPK) modeling is a type of in silico simulation that uses:

• Physiological parameters (organ volumes, blood flow rates)
• Drug-specific data (solubility, logP, clearance)
• Population data (age, sex, disease state)

to build a system of compartments that mimics the human body and predicts how the drug will move through it.

Why Combine PBPK with Phase 0?

Microdosing gives early human PK signals. PBPK modeling allows extrapolation to therapeutic doses. Together, they offer:

• Better prediction of dose-exposure relationships
• Evaluation of drug-drug interaction risk
• Simulation of special populations (pediatrics, renal impairment)
• Confidence in Phase 1 dosing strategy

Workflow: Combining Phase 0 with In Silico Tools

1. Pre-Study Model Development

• Use in vitro and animal ADME data to construct a draft PBPK model
• Include solubility, permeability, hepatic clearance, plasma protein binding
• Use commercial software like Simcyp®, GastroPlus®, PK-Sim®

2. Phase 0 Trial Execution

• Conduct microdosing study (oral/IV) with PK sampling
• Measure plasma levels, AUC, Cmax, and t½ using LC-MS/MS or AMS

3. Model Calibration

• Integrate observed Phase 0 data into the PBPK model
• Refine clearance or absorption assumptions
• Validate model using observed vs predicted plots

4. Simulation and Prediction

• Predict PK profile at intended therapeutic dose
• Run virtual trials in different populations (e.g., female, elderly, Asian ethnicity)
• Model impact of food, formulation changes, or IV-to-oral switch

Regulatory Acceptance of PBPK Modeling

Global regulators increasingly accept PBPK as part of clinical development submissions:

• FDA: Encourages PBPK in exploratory INDs and supports submissions in NDAs
• EMA: Publishes guidelines on using PBPK for dose selection and DDI prediction
• CDSCO: Accepts PBPK modeling results if backed by clinical data

Applications of PBPK with Phase 0

1. Dose Escalation Planning

Simulations help determine safe starting doses and escalation schemes for Phase 1 trials.

2. Bridging Across Routes

Use IV microdose data to model oral bioavailability or simulate alternate delivery routes.

3. Population Diversity

Model how genetic polymorphisms or organ dysfunction may affect drug levels—without needing immediate clinical trials in those groups.

4. Drug–Drug Interaction Potential

Simulate interaction with CYP inducers or inhibitors before full DDI studies are done.

Example: CNS Microdose PBPK Integration

A biotech company developed a CNS-active small molecule. Phase 0 showed detectable plasma levels but raised concerns about brain penetration. PBPK modeling predicted low CNS exposure at full dose, aligning with PET scan results. The team chose to modify the scaffold before proceeding to full development—saving significant time and cost.

Best Practices for Using In Silico Tools in Phase 0

• Use high-quality input data from validated in vitro and in vivo studies
• Document assumptions and limitations in every model
• Update models iteratively with real human data
• Work with multidisciplinary teams—modelers, clinicians, statisticians

Conclusion

Integrating PBPK and in silico modeling with Phase 0 trials transforms microdosing data into powerful predictive tools. It enables more confident decisions, smarter trial designs, and ultimately, faster and safer development. These digital simulations are not just hypothetical exercises—they are now a strategic pillar in modern clinical pharmacology.